PD-1 monoclonal antibody

Org: Department of Organ transplantation, the Third Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Faculty of Hepatopancreatobiliary Surgery, the First Medical Center of Chinese People’s Liberation Army (PLA) General Hospital,

Clinical trial

A Phase II Clinical Trial To Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Non-nasopharyngeal Carcinoma) and Other Solid Tumors

Status: Not yet recruiting, Estimated PCD: 2026-06-01

Clinical trial

The Safety and Efficacy Assessment of Allogeneic γδ T Cells Combined With Targeted Therapy and Immunotherapy in Hepatocellular Carcinoma Patients

Status: Not yet recruiting, Estimated PCD: 2026-04-26

Clinical trial

The Safety and Efficacy Assessment of Allogeneic γδ T Cells Combined With Targeted Therapy and Immunotherapy in Hepatocellular Carcinoma Patients

Status: Not yet recruiting, Estimated PCD: 2026-04-26

Clinical trial

A Single-arm, Open, Single-center, Prospective and Exploratory Clinical Study of Surufatinib Combined With Tislelizumab in the Treatment of Advanced Lung Cancer With Neuroendocrine Differentiation

Status: Not yet recruiting, Estimated PCD: 2026-06-01

Clinical trial

Prospective Phase II Study of Hypofractionated Radiotherapy Sequential Tislelizumab and Anlotinib in the Neoadjuvant and Adjuvant Therapy for Stage II-IIIA Non-Small Cell Lung Cancer

Status: Not yet recruiting, Estimated PCD: 2025-12-31

Clinical trial

Phase II, Open-Label Study of Preliminary Efficacy of Sitravatinib in Combination With Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.

Status: Active (not recruiting), Estimated PCD: 2023-12-31

Clinical trial

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

Status: Not yet recruiting, Estimated PCD: 2026-06-01

Clinical trial

Neoadjuvant Tislelizumab and Platinum-Based Doublet Chemotherapy in Stage II-IIIB EGFR-Mutated Lung Adenocarcinoma With PD-L1 Positive Expression -- A Phase II Study (DuoVitality)"

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

Phase II Study of Ablation Combined With PD-1 Antibody in Patients With Hepatocellular Carcinoma

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2025-05-31

Clinical trial

A Phase 1b Dose-escalation and Cohort-expansion Study of the Safety/Tolerability, and Efficacy of Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites (OPTIONS-02)

Status: Recruiting, Estimated PCD: 2025-03-20

Clinical trial

A Phase II Prospective Study to Evaluate the Safety and Efficacy of Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.

Status: Not yet recruiting, Estimated PCD: 2023-12-31

Clinical trial

A Prospective Clinical Study of Chemotherapy Plus Programmed Death-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-cell Lymphoma.

Status: Recruiting, Estimated PCD: 2023-04-18

Clinical trial

A Phase 1b/2 Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Status: Recruiting, Estimated PCD: 2024-02-07

Clinical trial

Prospective, Single-arm, Phase II Clinical Study of Tirellizumab Combined With Carboplatin and Paclitaxel Polymer Micelles Neoadjuvant Therapy for cN+ Head and Neck Squamous Cell Carcinoma

Status: Not yet recruiting, Estimated PCD: 2026-12-30

Clinical trial

Tislelizumab in Combination With Pre-operative Chemoradiotherapy Versus SOC for Patients With Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: a Multicenter, Randomized, Open-label, Phase IIB Trial

Status: Recruiting, Estimated PCD: 2027-02-28

Clinical trial

A Phase II, Randomized, Open-label Trial of Trilaciclib Prior to Chemotherapy Plus Tislelizumab as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Status: Not yet recruiting, Estimated PCD: 2024-10-31

Clinical trial

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer: a Phase II, Single-arm Study

Status: Not yet recruiting, Estimated PCD: 2024-04-05

Clinical trial

Phase II Clinical Study of Vitamin E Combined With Fruquintinib and Tislelizumab in Patients With Microsatellite Stabilized Metastatic Colorectal Cancer Who Failed Standard Therapy

Status: Not yet recruiting, Estimated PCD: 2025-02-01

Clinical trial

An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects

Status: Recruiting, Estimated PCD: 2025-08-01

Clinical trial

A Single-arm, Open-label, Multicenter Phase 2 Study to Evaluate XELOX + Tislelizumab in Combination With Doxorubicin Hydrochloride Liposome Injection （XELOX+PD-1+PLD）as Neoadjuvant Therapy for Resectable Gastric Cancer

Status: Recruiting, Estimated PCD: 2023-09-30

Clinical trial

Chemoradiation Versus Chemotherapy in Combination With Tislelizumab as First Line Treatment for Advanced Esophageal Squamous Cell Carcinoma With Low PD-L1 Expression (RENMIN-236): Multicentre, Randomised, Phase 3 Trial

Status: Recruiting, Estimated PCD: 2026-07-01

Clinical trial

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Status: Recruiting, Estimated PCD: 2027-06-01

Clinical trial

A Prospective, Open-label, Single-arm, Phase II Trial Investigating the Efficacy and Safety of Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

Status: Recruiting, Estimated PCD: 2025-07-07

Clinical trial

Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma (BTC): a Single Arm, Prospective, Interventional Clinical Study

Status: Not yet recruiting, Estimated PCD: 2025-04-30

Clinical trial

A Prospective, Multicenter, Phase II Trial to Evaluate the Efficacy of Zanubrutinib and Tislelizumab as Well as Standard of Care for the Treatment of Patients With Progressive Lymphoma Post Anti-CD19 CAR-T Cell Therapy

Status: Not yet recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Prospective, Phase II Trial Using Circulating Tumor DNA to Initiate Post-operation Boost Therapy After Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

Status: Recruiting, Estimated PCD: 2027-08-01

Clinical trial

A Phase 1b Dose-escalation and Cohort-expansion Study of the Safety/Tolerability, and Efficacy of Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Hepatocellular Carcinoma

Status: Recruiting, Estimated PCD: 2025-12-30

Clinical trial

CT-guided Thermal Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage Hepatocellular Carcinoma: a Randomized Controlled Phase II Clinical Trial

Status: Recruiting, Estimated PCD: 2023-12-18

Clinical trial

Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma: a Single-center, Prospective, Single-arm Study

Status: Not yet recruiting, Estimated PCD: 2025-12-30

Clinical trial

Efficacy of HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma: an Observational, Real-world Study

Status: Recruiting, Estimated PCD: 2024-12-30

Clinical trial

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Status: Recruiting, Estimated PCD: 2028-04-01

Clinical trial

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-M07D1+PD-1 Monoclonal Antibody and BL-M07D1+PD-1 Monoclonal Antibody+Capecitabine as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Status: Not yet recruiting, Estimated PCD: 2026-06-01

Clinical trial

Phase II Study of Tislelizumab Plus Pemetrexed in Patients With Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

Multicenter, Single-arm, Open-label Phase II Clinical Study of Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

Status: Not yet recruiting, Estimated PCD: 2024-12-31

Clinical trial

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Newly Diagnosed Stage Ⅲ Unresectable Non-small Cell Lung Cancer: a Open-label, Single-arm Prospective Clinical Trial

Status: Recruiting, Estimated PCD: 2024-12-31

Abstract

Clinical analysis of immunotherapy rechallenge in advanced gastric cancer.

Org: Henan Cancer Hospital, China National Biotec Group, Zhengzhou Gensciences, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,

Product

QL1604

Clinical trial

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Status: Recruiting, Estimated PCD: 2026-11-30

Product

Hypofractionated radiotherapy + Tislelizumab + Anlotinib

Product

serplulimab, (nab-) paclitaxel, carboplatin

Product

tislelizumab + eribulin + anlotinib

Product